Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant cagrisema is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over #semaglutide 2.4mg week! Cagrisema is a fixed dose combination of semaglutide 2.4mg + # Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Semaglutide Dosage Chart for Weight Loss & Dosing Guide Ro Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth